SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BioMarin Pharmaceutical Inc. (BMRN) trades at a trailing P/E of 30.9, forward P/E of 12.8. Trailing earnings yield is 3.24%, forward earnings yield 7.79%. PEG 0.09 (Peter Lynch undervalued ≤1.0). Graham Number is $36.04.
Criteria proven by this page:
- VALUE (81/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.09); analyst target implies upside (+56.1%).
- Forward P/E 12.8 (down from trailing 30.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.09 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.24% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 7.79% as earnings recover.
- Analyst consensus target $86.60 (+56.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 82/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
81/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BMRN
Valuation Multiples
P/E (TTM)30.9
Forward P/E12.8
PEG Ratio0.09
Forward PEG0.09
P/B Ratio1.77
P/S Ratio3.36
EV/EBITDA17.7
Per Share Data
EPS (TTM)$1.82
Forward EPS (Est.)$4.32
Book Value / Share$31.74
Revenue / Share$16.80
FCF / Share$3.78
Yields & Fair Value
Earnings Yield3.24%
Forward Earnings Yield7.79%
Dividend Yield0.00%
Graham Number$36.04
SharesGrow IV$146.18 (+163.5%)
Analyst Target$86.60 (+56.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-21.8 |
-0.09 |
4.97 |
12.31 |
- |
| 2017 |
-132.9 |
1.61 |
5.54 |
11.84 |
- |
| 2018 |
-195.3 |
5.69 |
5.08 |
10.11 |
- |
| 2019 |
-634.8 |
9.01 |
4.85 |
8.88 |
- |
| 2020 |
18.6 |
0.00 |
3.86 |
8.52 |
- |
| 2021 |
-252.1 |
2.35 |
3.79 |
8.75 |
- |
| 2022 |
135.4 |
-0.43 |
4.17 |
9.15 |
- |
| 2023 |
108.0 |
6.32 |
3.66 |
7.49 |
- |
| 2024 |
29.3 |
0.19 |
2.21 |
4.38 |
- |
| 2025 |
32.7 |
-1.71 |
1.87 |
3.54 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.79 |
$1.12B |
$-630.21M |
-56.4% |
| 2017 |
$-0.67 |
$1.31B |
$-117.04M |
-8.9% |
| 2018 |
$-0.44 |
$1.49B |
$-77.21M |
-5.2% |
| 2019 |
$-0.13 |
$1.7B |
$-23.85M |
-1.4% |
| 2020 |
$4.53 |
$1.86B |
$854.03M |
45.9% |
| 2021 |
$-0.35 |
$1.85B |
$-64.08M |
-3.5% |
| 2022 |
$0.75 |
$2.1B |
$141.56M |
6.8% |
| 2023 |
$0.87 |
$2.42B |
$167.65M |
6.9% |
| 2024 |
$2.06 |
$2.85B |
$426.86M |
15% |
| 2025 |
$1.80 |
$3.22B |
$348.9M |
10.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.32 |
$4.09 – $4.89 |
$3.62B |
$3.6B – $3.66B |
9 |
| 2027 |
$5.37 |
$4.32 – $5.88 |
$4.03B |
$3.75B – $4.13B |
8 |
| 2028 |
$6.76 |
$4.90 – $9.01 |
$4.42B |
$4.18B – $4.66B |
8 |
| 2029 |
$7.57 |
$7.19 – $7.96 |
$4.79B |
$4.61B – $4.98B |
6 |
| 2030 |
$8.40 |
$7.98 – $8.82 |
$5.08B |
$4.89B – $5.28B |
6 |
